InfectionPhase 4LDAWB-2001NCT00176124
Leukocyte Depletion of Autologous Whole Blood
A Phase 4 study testing leukocyte depletion of whole blood and Leukocyte filtration/Depletion in people with Infection and Bacterial Infection, run by Heidelberg University at 3 sites in Germany.
Trial summary
Leukocyte depletion of autologous whole blood prior to storage does not reduce infection rate (wound, urinary tract, other), use of antibiotic treatment and length of hospital stay but may increase retransfusion perioperatively during hip arthroplasty and allogenic transfusion rate Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Infection, Bacterial Infection, Sepsis
- What is being tested?
- leukocyte depletion of whole blood and Leukocyte filtration/Depletion
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,089 participants
- Where
- 3 sitesGermany
- Study dates
- Apr 2001to Sep 2005
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- • ASA I-III,
- Age 18-85 years,
- Body weight 50-125 kg
- If female, with either a history of an accepted method of anticonception for at least 3 month prior and 1 month following the termination of the study or climacteric or with a negative betA- HCG-Test in urine or serum.
- Preoperative blood donation of at least 2 units (450mL whole blood)
- Preoperative hemoglobin level > 10 mg/dL
- Able and willing to sign informed consent
Who cannot join
- Subjects with a contraindication for preoperative blood donation (PAD) (in 12, PP 36-43).
- systemic infection
- acute bacterial or viral diseases
- anemia (Hb > 11g/dL)
- myocardial infarction within the past 6 month,
- instable angina pectoris
Show all 19Show fewer
- vascular stenosis (i.e. of the coronary or internal carotid arteries)
- hemodynamic relevant valvular stenosis
- heart failure > NYHA II
- history of strokes or TIA
- steroid therapy,
- immune deficiency,
- hematological or endocrinological disease,
- coagulopathy,
- history of organ transplantation,
- simultaneous participation in a second study
- pregnancy
- membership at Jehovah's Witnesses
- intended use of a cell saver
Trial locations and contacts
3 sites in 1 country.
Germany3 sites
Klinikum Garmisch Partenkirchen
Garmisch-Partenkirchen, Bavaria, 82467
Clinic of Anesthesiology and Critical Care Medicine, Faculty of Clinical Medicine MAnnheim, University of Heidelberg, Germany
Mannheim, Baden-Wurttemberg, 68167
Institute of Transfusion Medicine and Hemostasiology, University of MArburg
Marburg, 35043
About this study
Official title: Leukocyte Depletion of Autologous Whole Blood: Impact on Perioperative Infection Rate and Length of Hospital Stay for Hip Arthroplasty Patients
Leukocyte depletion of autologous whole blood prior to storage does not reduce infection rate (wound, urinary tract, other), use of antibiotic treatment and length of hospital stay but may increase retransfusion perioperatively during hip arthroplasty and allogenic transfusion rate
Read the detailed description
Informed Consent Form:
Prior to the first blood donation, in- and exclusion criteria should be tested. Then the patient is to inform by the investigator about the studies aim and participation conditions such as methods, risks, assurance, data security, etc. The patient and the investigator should sign the informed consent form.
Randomization:
If all inclusion criteria are well given and exclusion criteria are absent, the patient could be enrolled and randomized, prior to the first PAD. Enrollment is parallel in all centers until the final number of 1088 is reached. Breaking the seal of the provided randomization envelope with computerized randomization codes completes randomization. Time and date should be noted.
Blinding:
Randomization is done by the investigator, which should manage the blood donation. The blood bags after inline leukocyte depletion prior to storage do not look different from not depleted bags and are labeled only with the patient's identity and the subjects ID. The allocation to the group is to keep secret from patient, surgeon and anesthesiologist.
Treatment:
A PAD:
Group 1 Preoperative Donation of multiple units ( more than 2) 450 mL autologous whole blood and storage without leukocyte depletion Usual criteria and methods of PAD are used according to regional guidelines of blood donations in the respective center.
Group 2 Preoperative Donation of multiple units (more than 2) 450 mL autologous whole blood and storage following leukocyte depletion 2 to 4 hours after whole blood donations, the whole blood bags should be in-line filtered by the use of leukocyte filtration sets (provided by Pall Medical Company). Storage as in group 1 at 4 degree C in a blood fridge.
A as proposal, the Mannheim concept reveals a 95 percent security in avoidance of allogenic transfusions for a blood loss of 20-25 ml per kg body weight: Intended are 3 donations in weekly intervals. If Hb plasma con-tent decreases below 11 g/dL, the donation will be postponed to the fol-lowing week. Surgery is at the fifth week after the first donation.
B Anesthesia and Surgery:
As usual in the center, and without a difference between the two groups anesthesia and surgery should be performed under following aspects:
- At hospital admission, the actual history should be taken, study measures (Appendix 1) and screening laboratory should be withdrawn prior to anesthesia to compute the infection risk assessment of the respective patient 13.
- Both general and regional (spinal or epidural anesthesia) can be performed
- Normothermia of the patients is essential to the infection rate, hypothermia increases the infection rate by every degree! The intra- and postoperative core temperature range will be requested.
- Circulatory monitoring should be performed according to the centers conventions. Monitoring with a 5 channel ECG is suggested. Normovolemia is essential because hypovolemia is related to increased infection rate by hypoperfusion of the wound14-16. Therefore, a central venous catheter is useful but not obligatory, but urine output is required since it is a more sensitive volume indicator in absence of significant heart and renal failure (and common practice in hip surgery). An arterial line is not obligatory required.
- Bladder catheter (Urine production more than 1ml/kg KG/h)
- Cell Savers and hemodilution (iso- or hypervolemic) are not accepted.
- Blood loss is to calculate carefully by subtracting rinsing from suction volumes and weighing sponges and drapes intraoperatively. Postoperatively the drainage volumes are sufficient if not massive expansion of thighs or hip occurs ( however, this should be noted as AE).
- In the case that allogenic transfusion is required additionally, this should be leukodepleted.
- Intra- und postoperative transfusion trigger are similar for autologous and allogenic transfusion:
- Hb greater than 8,5 plus minus 0,5
- HF over 100 plusminus 10 /min or 35% above base line
- MAP below 60 plusminus 5 mmHg or 35% below base line
- Stenocardia, chest pain
- ST-segment changes greater than 0,2 ms
Further documentation of
- ASA
- sex
- weight
- height
- Anesthesia duration
- OP-duration
- Blood loss(intra- and postoperatively)
- Lowest diastole. RR intraoperatively as well as postoperatively POD 0
- Time of transfusions
- Time of urine catheter withdrawal Infection-Monitoring
Parameter:
- Skin inspection
Criteria of wound infection:
- secretion clear or pus,
- pos. bacterial culture,
- erythema
- Urine culture if indicated by sediment (at withdrawl of bladder cathe-ter, discolored urine or fever)
- Blood culture (if fever above 39°C after POD2)
- Tracheal secretion (if expectoration is prutride or radiological indica-tion of bronchopneumonia)
- Antibiotic treatment, duration, amounts, multidrug use
Woundhealing and the occurrence of infections were classified with the ASEPSIS score: Of influence is the duration of antibiotic treatment, drainage of pus, wound de-bridements, erythema, involvement of deeper tissue layers, identification of bacteria, LOS above 14 days 17.
Infection Definition
Occurrence of any infection is defined as
- Elevation of patient's temperature/fever above 38°C on POD 3 or later or
- Leukocytosis above the cut off point (generated for every individual subject )or
- BSG / CRP above the cut off point (generated for every individual subject ) or
- Isolation of bacteria from any fluid including pus or
- Abscess (verificated by surgical drainage or ultrasonographically guided aspiration of pus ) or
- Arthritis by local clinical symptoms and surgical drainage
Wound infection is assessed by the ASEPSIS score
Urinary tract infection is defined as
- new isolated occurrence of leukocytosis, and/or nitrite, and/or protein or
- isolation of bacteria more than 10 000/µl (sediment) or
- growth of more than 100 000 colonies of a single organism in the culture
Respiratory airway infection is defined as
- positive x-ray (chest infiltrate) and fever or
- dyspnea or cough or purulent sputum and fever or
- isolation of bacteria in tracheal secretion (only intubated subjects) and fever
Septicemia is defined as
- clinical symptoms and positive blood culture
- Conditions
- Infection, Bacterial Infection, Sepsis
- Being tested
- leukocyte depletion of whole blood, Leukocyte filtration/Depletion
- Keywords
- leukocyte depletion, autologous transfusion,, infection, bacterial infection, sepsis, antibiotics
- Medical subject headings
- Infections, Bacterial Infections, Sepsis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
leukocyte depletion of whole bloodProcedure or surgery
Leukocyte filtration/DepletionOther
Also called Fresenius leukocyte depletion whole blood filters
leukocyte depletion filters as used routinely: filters (prestorage) inherent to the blood bag sets by gravity force following storage on cold plate for 2 hours
| Study group | Role | What they receive |
|---|---|---|
| 1 | No intervention | storage and transfusion of autologous whole blood without leukocyte depletion : Control group Receives: Procedure: leukocyte depletion of whole blood |
| 2 | Experimental | storage and transfusion of leukocyte depleted autologous whole blood : leukocyte depletion group Receives: Procedure: leukocyte depletion of whole blood; Other: Leukocyte filtration/Depletion |
What is being measured
The primary outcome is the main question the study is designed to answer.
Comparison of infection rate (wound, urinary tract, other), use of antibiotic treatment and length of hospital stay
Measured: 90 days
Secondary outcomes (1)
Blood loss and transfusion rate
Measured: 90 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Sep 2005 (estimated)
- Study startApr 2001
- Primary completionApr 2005
- Study completionSep 2005
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for InfectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 1,089 participants (actual)
Sponsor and investigators
- Lead sponsor
- Heidelberg University
- Sponsor type
- University, hospital or other
- Collaborators
- Philipps University Marburg
- Investigators
- Thomas Frietsch, MD, PhD, Study chair, Clinic of Anesthesiology and Critical Care Medicine, Faculty of Clinical Medicine Mannheim, University of Heidelberg
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00176124
- Sponsor's protocol ID
- UniKlinMa-TF-2001-1
- Other IDs
- ISRCTN 99578441
- Acronym
- LDAWB-2001
- Status last verified
- Jun 2008
- First submitted
- 11 Sep 2005
- Last updated
- 10 Jun 2008
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Byrne DJ, Malek MM, Davey PG, Cuschieri A. Postoperative wound scoring. Biomed Pharmacother. 1989;43(9):669-73. doi: 10.1016/0753-3322(89)90085-1.
PubMed 2696565Frietsch T, Fessler H, Kirschfink M, Nebe T, Waschke KF, Lorentz A. Immune response to autologous transfusion in healthy volunteers: WB versus packed RBCs and FFP. Transfusion. 2001 Apr;41(4):470-6. doi: 10.1046/j.1537-2995.2001.41040470.x.
PubMed 11316896Frietsch T, Krombholz K, Tolksdorf B, Nebe T, Segiet W, Lorentz A. Cellular immune response to autologous blood transfusion in hip arthroplasty: whole blood versus buffy coat-poor packed red cells and fresh-frozen plasma. Vox Sang. 2001 Oct;81(3):187-93. doi: 10.1046/j.1423-0410.2001.00107.x.
PubMed 11703863Lorentz A, Osswald PM, Schilling M, Jani L. [A comparison of autologous transfusion procedures in hip surgery]. Anaesthesist. 1991 Apr;40(4):205-13. German.
PubMed 2058822Tolksdorf B, Frietsch T, Quintel M, Kirschfink M, Becker P, Lorentz A. Humoral immune response to autologous blood transfusion in hip surgery: whole blood versus packed red cells and plasma. Vox Sang. 2001 Oct;81(3):180-6. doi: 10.1046/j.1423-0410.2001.00106.x.
PubMed 11703862Frietsch T, Lorentz A. Predonation of autologous blood is jeopardized by new regulations. Eur J Anaesthesiol. 2001 Oct;18(10):629-31. doi: 10.1046/j.1365-2346.2001.00997.x. No abstract available.
PubMed 11553239
Study at a glance
From the registry record, last updated by the sponsor on 10 Jun 2008. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Leukocyte Depletion of Autologous Whole Blood: Impact on Perioperative Infection Rate and Length of Hospital Stay for Hip Arthroplasty Patients
- ClinicalTrials.gov ID
- NCT00176124
- Acronym / sponsor ID
- LDAWB-2001 / UniKlinMa-TF-2001-1
- Conditions
- Infection, Bacterial Infection, Sepsis
- Keywords
- leukocyte depletion, autologous transfusion,, infection, bacterial infection, sepsis, antibiotics
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,089 participants (actual)
- Lead sponsor
- Heidelberg UniversityUniversity, hospital or other
- Collaborators
- Philipps University Marburg
- Study start
- Apr 2001
- Primary completion
- Apr 2005 (actual)
- Study completion
- Sep 2005 (actual)
- First posted
- 15 Sep 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Leukocyte depletion of autologous whole blood prior to storage does not reduce infection rate (wound, urinary tract, other), use of antibiotic treatment and length of hospital stay but may increase retransfusion perioperatively during hip arthroplasty and allogenic transfusion rate
Detailed description
Informed Consent Form:
Prior to the first blood donation, in- and exclusion criteria should be tested. Then the patient is to inform by the investigator about the studies aim and participation conditions such as methods, risks, assurance, data security, etc. The patient and the investigator should sign the informed consent form.
Randomization:
If all inclusion criteria are well given and exclusion criteria are absent, the patient could be enrolled and randomized, prior to the first PAD. Enrollment is parallel in all centers until the final number of 1088 is reached. Breaking the seal of the provided randomization envelope with computerized randomization codes completes randomization. Time and date should be noted.
Blinding:
Randomization is done by the investigator, which should manage the blood donation. The blood bags after inline leukocyte depletion prior to storage do not look different from not depleted bags and are labeled only with the patient's identity and the subjects ID. The allocation to the group is to keep secret from patient, surgeon and anesthesiologist.
Treatment:
A PAD:
Group 1 Preoperative Donation of multiple units ( more than 2) 450 mL autologous whole blood and storage without leukocyte depletion Usual criteria and methods of PAD are used according to regional guidelines of blood donations in the respective center.
Group 2 Preoperative Donation of multiple units (more than 2) 450 mL autologous whole blood and storage following leukocyte depletion 2 to 4 hours after whole blood donations, the whole blood bags should be in-line filtered by the use of leukocyte filtration sets (provided by Pall Medical Company). Storage as in group 1 at 4 degree C in a blood fridge.
A as proposal, the Mannheim concept reveals a 95 percent security in avoidance of allogenic transfusions for a blood loss of 20-25 ml per kg body weight: Intended are 3 donations in weekly intervals. If Hb plasma con-tent decreases below 11 g/dL, the donation will be postponed to the fol-lowing week. Surgery is at the fifth week after the first donation.
B Anesthesia and Surgery:
As usual in the center, and without a difference between the two groups anesthesia and surgery should be performed under following aspects:
- At hospital admission, the actual history should be taken, study measures (Appendix 1) and screening laboratory should be withdrawn prior to anesthesia to compute the infection risk assessment of the respective patient 13.
- Both general and regional (spinal or epidural anesthesia) can be performed
- Normothermia of the patients is essential to the infection rate, hypothermia increases the infection rate by every degree! The intra- and postoperative core temperature range will be requested.
- Circulatory monitoring should be performed according to the centers conventions. Monitoring with a 5 channel ECG is suggested. Normovolemia is essential because hypovolemia is related to increased infection rate by hypoperfusion of the wound14-16. Therefore, a central venous catheter is useful but not obligatory, but urine output is required since it is a more sensitive volume indicator in absence of significant heart and renal failure (and common practice in hip surgery). An arterial line is not obligatory required.
- Bladder catheter (Urine production more than 1ml/kg KG/h)
- Cell Savers and hemodilution (iso- or hypervolemic) are not accepted.
- Blood loss is to calculate carefully by subtracting rinsing from suction volumes and weighing sponges and drapes intraoperatively. Postoperatively the drainage volumes are sufficient if not massive expansion of thighs or hip occurs ( however, this should be noted as AE).
- In the case that allogenic transfusion is required additionally, this should be leukodepleted.
- Intra- und postoperative transfusion trigger are similar for autologous and allogenic transfusion:
- Hb greater than 8,5 plus minus 0,5
- HF over 100 plusminus 10 /min or 35% above base line
- MAP below 60 plusminus 5 mmHg or 35% below base line
- Stenocardia, chest pain
- ST-segment changes greater than 0,2 ms
Further documentation of
- ASA
- sex
- weight
- height
- Anesthesia duration
- OP-duration
- Blood loss(intra- and postoperatively)
- Lowest diastole. RR intraoperatively as well as postoperatively POD 0
- Time of transfusions
- Time of urine catheter withdrawal Infection-Monitoring
Parameter:
- Skin inspection
Criteria of wound infection:
- secretion clear or pus,
- pos. bacterial culture,
- erythema
- Urine culture if indicated by sediment (at withdrawl of bladder cathe-ter, discolored urine or fever)
- Blood culture (if fever above 39°C after POD2)
- Tracheal secretion (if expectoration is prutride or radiological indica-tion of bronchopneumonia)
- Antibiotic treatment, duration, amounts, multidrug use
Woundhealing and the occurrence of infections were classified with the ASEPSIS score: Of influence is the duration of antibiotic treatment, drainage of pus, wound de-bridements, erythema, involvement of deeper tissue layers, identification of bacteria, LOS above 14 days 17.
Infection Definition
Occurrence of any infection is defined as
- Elevation of patient's temperature/fever above 38°C on POD 3 or later or
- Leukocytosis above the cut off point (generated for every individual subject )or
- BSG / CRP above the cut off point (generated for every individual subject ) or
- Isolation of bacteria from any fluid including pus or
- Abscess (verificated by surgical drainage or ultrasonographically guided aspiration of pus ) or
- Arthritis by local clinical symptoms and surgical drainage
Wound infection is assessed by the ASEPSIS score
Urinary tract infection is defined as
- new isolated occurrence of leukocytosis, and/or nitrite, and/or protein or
- isolation of bacteria more than 10 000/µl (sediment) or
- growth of more than 100 000 colonies of a single organism in the culture
Respiratory airway infection is defined as
- positive x-ray (chest infiltrate) and fever or
- dyspnea or cough or purulent sputum and fever or
- isolation of bacteria in tracheal secretion (only intubated subjects) and fever
Septicemia is defined as
- clinical symptoms and positive blood culture
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 1 | No intervention | Procedure: leukocyte depletion of whole bloodstorage and transfusion of autologous whole blood without leukocyte depletion : Control group |
| 2 | Experimental | Procedure: leukocyte depletion of whole blood, Other: Leukocyte filtration/Depletionstorage and transfusion of leukocyte depleted autologous whole blood : leukocyte depletion group |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- • ASA I-III,
Key exclusion criteria (19 listed)
- Subjects with a contraindication for preoperative blood donation (PAD) (in 12, PP 36-43).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| leukocyte depletion of whole blood | Procedure or surgery | 1, 2 |
| Leukocyte filtration/DepletionAlso: Fresenius leukocyte depletion whole blood filtersleukocyte depletion filters as used routinely: filters (prestorage) inherent to the blood bag sets by gravity force following storage on cold plate for 2 hours | Other | 2 |
Primary outcome
Comparison of infection rate (wound, urinary tract, other), use of antibiotic treatment and length of hospital stay
Time frame: 90 days
1 secondary outcome
Blood loss and transfusion rate
Time frame: 90 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jun 2008.
- Background: PubMed 2696565Byrne DJ, Malek MM, Davey PG, Cuschieri A. Postoperative wound scoring. Biomed Pharmacother. 1989;43(9):669-73. doi: 10.1016/0753-3322(89)90085-1.
- Background: PubMed 11316896Frietsch T, Fessler H, Kirschfink M, Nebe T, Waschke KF, Lorentz A. Immune response to autologous transfusion in healthy volunteers: WB versus packed RBCs and FFP. Transfusion. 2001 Apr;41(4):470-6. doi: 10.1046/j.1537-2995.2001.41040470.x.
- Background: PubMed 11703863Frietsch T, Krombholz K, Tolksdorf B, Nebe T, Segiet W, Lorentz A. Cellular immune response to autologous blood transfusion in hip arthroplasty: whole blood versus buffy coat-poor packed red cells and fresh-frozen plasma. Vox Sang. 2001 Oct;81(3):187-93. doi: 10.1046/j.1423-0410.2001.00107.x.
- Background: PubMed 2058822Lorentz A, Osswald PM, Schilling M, Jani L. [A comparison of autologous transfusion procedures in hip surgery]. Anaesthesist. 1991 Apr;40(4):205-13. German.
- Background: PubMed 11703862Tolksdorf B, Frietsch T, Quintel M, Kirschfink M, Becker P, Lorentz A. Humoral immune response to autologous blood transfusion in hip surgery: whole blood versus packed red cells and plasma. Vox Sang. 2001 Oct;81(3):180-6. doi: 10.1046/j.1423-0410.2001.00106.x.
- Background: PubMed 11553239Frietsch T, Lorentz A. Predonation of autologous blood is jeopardized by new regulations. Eur J Anaesthesiol. 2001 Oct;18(10):629-31. doi: 10.1046/j.1365-2346.2001.00997.x. No abstract available.
Related trials for Infection
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
RecruitingObservational study
Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis
Hepatitis D
RecruitingObservational study
VIRal Pulmonary Infections in Older AGE
Viral Pulmonary Infections
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Thomas Frietsch, MD, PhD study chair
Clinic of Anesthesiology and Critical Care Medicine, Faculty of Clinical Medicine Mannheim, University of Heidelberg
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing leukocyte depletion of whole blood and Leukocyte filtration/Depletion in people with Infection and Bacterial Infection, run by Heidelberg University at 3 sites in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Jun 2008. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Comparison of infection rate (wound, urinary tract, other), use of antibiotic treatment and length of hospital stay (time frame: 90 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00176124, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jun 2008.